Table 2.
Summary of network meta-analysis results for overall survival and progression-free survival.
| Treatment arm | OS | PFS |
|---|---|---|
| P value of Overall heterogeneity/inconsistency | 0.66 | 0.17 |
| P value of heterogeneity (within designs) | 0.66 | 0.17 |
| P value of heterogeneity (between designs) | / | / |
| Docetaxel | ||
| HR | 1.00 | 1.00 |
| P-score (%) | 0 | 13.5 |
| Anti-PD-1 | ||
| HR (95% CI) | 0.56 (0.48-0.66) | 0.75 (0.62-0.89) |
| P-score (%) | 91.2 | 95.5 |
| Anti-PD-L1 | ||
| HR (95% CI) | 0.64 (0.51-0.79) | 0.92 (0.72-1.19) |
| P-score (%) | 58.8 | 41.0 |
Abbreviations: OS = overall survival; PFS = progression-free survival; PD-1 = programmed death 1; PD-L1 = programmed death ligand 1; HR = hazard ratio; CI = confidence interval.
Fixed-effects model was used for overall survival and progression-free survival.